Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-02-2019 | Original Article – Clinical Oncology

Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer

Authors: Bin Huang, Hua Wang, Hao Lin, Zhijun Yao, Jiabo Zheng, Wenzhe Fan, Shaopeng Qiu, Lingwu Chen, Junxing Chen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2019

Abstract

Objective

Comparing intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone in the treatment of T1-staged Grade 3 (T1G3) bladder cancer after transurethral resection of bladder tumor (TURBT).

Materials and methods

From January 2007 to December 2012, 203 patients diagnosed with NMIBC were randomly assigned into either intra-arterial chemotherapy combined with intravesical chemotherapy group (Group A, n = 68) or intravesical chemotherapy alone group (Group B, n = 135) after TURBT. Four cycles of intra-arterial chemotherapy were administered after initial TURBT with 1-month interval between each. Intravesical chemotherapy was administered in both groups including an immediate 50 mg epirubicin instillation after TURBT and weekly maintenance for 8 weeks, and then followed by monthly maintenance for 1 year. The primary endpoint was recurrence-free survival.

Results

Out of 203 patients, 53 were in Group A and 98 in Group B, and they were evaluated for recurrence and progression rate where recurrence rate was 35.8% (19/53) in group A and 41.8% (41/98) in group B with a significant difference (P < 0.05) and progression rate was 20.7% (11/53) in group A and 23.5% (23/98) in group B with a significant difference (P < 0.05). Univariate and multivariate logistic regression analysis suggested that intra-arterial chemotherapy could be an independent risk factors related to both overall survival and time to first recurrence.

Conclusions

Intra-arterial chemotherapy combined with intravesical chemotherapy could reduce the risk of recurrence and progression compared to intravesical chemotherapy alone in T1G3 bladder cancer.

Chang SS et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029CrossRefPubMed

Eapen L et al (2004) Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 172(4 Pt 1):1276–1280CrossRefPubMed

Hoshi S et al (1997) Internal iliac arterial infusion chemotherapy for rabbit invasive bladder cancer. Int J Urol 4(5):493–499CrossRefPubMed

Kubota Y, Kakizaki H, Numasawa K (1986) Pre-operative one-shot intra-arterial infusion chemotherapy of bladder cancer. 2. The evaluation of the clinical usefulness of adriamycin and cisplatin. Nihon Hinyokika Gakkai Zasshi 77(6):909–913

Kunimoto S et al (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4′-O-tetrahydropyranyl adriamycin. J Antibiot (Tokyo) 36(3):312–317CrossRef

Li G et al (2017) Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis. Clin Invest Med 40(2):E81–E94CrossRefPubMed

Liang S et al (2015) Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection. Urol Int 94(4):406–411CrossRefPubMed

Liu Z et al (2018) The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer. World J Urol 36(8):1191–1200CrossRefPubMed

Martin-Doyle W et al (2015) Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 33(6):643–650CrossRef

Roupret M et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73(1):111–122CrossRef

Skarlos DV et al (1997) Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study. Eur Urol 31(4):420–427CrossRef

Spiess PE, Cancer B et al (2017) Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(10):1240–1267CrossRefPubMed

Sun F et al (2017) A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer. Cancer Chemother Pharmacol 79(6):1099–1107CrossRef

Sylvester RJ, van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970CrossRef

Sylvester RJ et al (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(6 Suppl 1):90–107CrossRefPubMed

Sylvester RJ et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766–773CrossRef

Woldu SL, Bagrodia A, Lotan Y (2017) Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 119(3):371–380CrossRefPubMedPubMedCentral

Zhang Y et al (2016) Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. Onco Targets Ther 5(Suppl 1):605–611

Title: Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer
Authors: Bin Huang
Hua Wang
Hao Lin
Zhijun Yao
Jiabo Zheng
Wenzhe Fan
Shaopeng Qiu
Lingwu Chen
Junxing Chen
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2811-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer

Abstract

Objective

Materials and methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Glioma stem cells reconstruct similar immunoinflammatory microenvironment in different transplant sites and induce malignant transformation of tumor microenvironment cells

Gynecologic radiation oncology patients report unmet needs regarding sexual health communication with providers

Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial

Preoperative brain MRI for clinical stage IA lung cancer: is routine scanning rational?

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page